低剂量紫杉醇联合顺铂同步分程每日两次再程放疗治疗复发性头颈鳞癌的II期研究:NRG肿瘤RTOG 9911长期随访
NRG肿瘤RTOG 9911是一项II期试验,评估分程每日两次再程放疗同步紫杉醇和顺铂治疗既往照射野内复发性头颈鳞癌或第二原发肿瘤。
要点
- 治疗相关死亡9例(9%),急性5例、晚期4例
- 1年生存者5年晚期4-5级毒性累积发生率22.4%
核心结论
- 尽管5级毒性发生率高,该试验的OS率超过历史对照的单纯化疗结果。
研究设计与样本
- II期试验纳入既往照射野内可测量复发性头颈鳞癌或第二原发肿瘤患者,体能状态0-1。
- 患者接受分程每日两次放疗(1.5 Gy/次,每日两次,每2周连用5天,共4周期),同步顺铂15 mg/m2每日×5和紫杉醇20 mg/m2每日×5,每2周重复,共4周期。
- 主要终点为相对历史对照RTOG 9610的OS,次要终点包括无进展生存、毒性和失败模式。
主要发现
- 2000年3月至2003年6月入组105例,100例可分析(76%男性,中位年龄60岁)。
- 原发部位以口咽(41%)和口腔(27%)为主,23%为第二原发肿瘤,既往放疗中位剂量65.7 Gy。
- 73%患者完成全部化疗,9例(9%)发生治疗相关死亡。
- 5年无进展生存率为7.0%(95% CI 2.0-12.0);64.9%死于原发癌症,3.2%死于第二原发肿瘤,22.3%死于非癌症或未知原因。
临床怎么用
- 对于不可切除的既往照射野内复发性头颈鳞癌或第二原发肿瘤,可考虑分程每日两次再程放疗同步紫杉醇和顺铂,但需警惕高发5级毒性。
局限性
- 本研究为单臂II期试验,主要终点基于历史对照比较。
- 样本量有限,长期生存者晚期毒性累积发生率高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Locoregionally recurrent squamous cell carcinoma of the head and neck and second primary tumors (SPTs) in previously irradiated fields, if not resectable, are virtually always fatal. Chemotherapy alone yields a median survival of 10 to 11 months and 5-year overall survival (OS) rates of <5%. Concurrent reirradiation and chemotherapy constitutes an alternative, nonstandard strategy. Herein, we report the long-term outcomes of NRG Oncology Radiation Therapy Oncology Group 9911, a phase II trial of split-course radiation therapy (RT) and concurrent paclitaxel and cisplatin. METHODS AND MATERIALS: Eligibility stipulated measurable, recurrent squamous cell carcinoma of the head and neck or SPT in previously irradiated fields, performance status 0-1, and adequate end-organ indices. Patients received split course, twice-daily RT (1.5 Gy/fraction twice a day × 5 days every 2 weeks ×4), plus cisplatin (15 mg/m2every day × 5) and paclitaxel (20 mg/m2every day ×5) every 2 weeks for 4 cycles. Granulocyte colony-stimulating factor was administered on days 6 to 13 of each 2-week cycle. The primary endpoint was OS relative to historical control, NRG Oncology Radiation Therapy Oncology Group 9610. Secondary endpoints included progression-free survival, toxicities, and patterns of failure. RESULTS: Between March 2000 and June 2003, 105 patients were enrolled; 100 patients were analyzable (76% male, median age 60 years). Oropharynx (41%) and oral cavity (27%) were the predominant primary sites. A total of 23% had SPT. Median prior RT dose was 65.7 Gy. Overall, 73% of patients completed all chemotherapy. Nine treatment-related deaths (9%) occurred: 5 in the acute and 4 in the late setting. Survival was significantly improved over historical control (P = .01) with 5-year survival increased from 3.8% (95% CI, 0.0-8.0) to 14.9% (95% CI, 7.9-21.9). Five-year progression-free survival was 7.0% (95% CI, 2.0-12.0). A total of 64.9% died of incident cancer, 3.2% of SPT, and 22.3% of noncancer or unknown causes. In 1-year survivors, the rate of subsequent late grade 4-5 toxicity was significantly higher than historical control (P = .02), with 5-year cumulative incidence of 22.4% (95% CI, 11.8-35.1) compared with 3.2% (95% CI, 0.2-14.5). CONCLUSIONS: Despite a high incidence of grade 5 toxicity, OS rates for this trial evaluating concurrent split course twice a day reirradiation with cisplatin and paclitaxel exceeded results seen historically with chemotherapy alone.
引用
- Langer CJ, Harris J, Horwitz EM, et al. Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911. Int J Radiat Oncol Biol Phys. 2025. PMID: 40752652. doi:10.1016/j.ijrobp.2025.07.1434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。